One of the most promising new compound classes in clinical development for the 33 treatment of malaria is the imidazolopiperazines (IZPs) class. Human trials have demonstrated 34 that members of the IZP series, which includes KAF156 (Ganaplacide) and GNF179, are potent 35 and effective against Plasmodium symptomatic asexual blood-stage infections. Unlike other 36 commonly used antimalarials, they also prevent transmission and block future infection in 37 animal models. Despite the identification of several Plasmodium falciparum resistance 38 mechanisms including mutations in ER-localized PfCARL (PfEMP65), Acetyl-coA transporter, 39 and PfUGT transporter, IZP's mechanism of action remains unknown. 40
golgicidin as well as synthetic lethality with PfSEC62. Our data show that IZPs target the 48 secretory pathway and highlight a novel mechanism for blocking parasite growth and 49 development that is distinct from those of standard compounds used to treat malaria. In addition, 50 we provide physiological signatures and hallmarks for inhibitors that work through this 51 mechanism of action and show that IZPs are tool compounds for studying ER-dependent protein 52 processing in different species. 53
54

INTRODUCTION
Parasites treated with IZPs have also been subjected to metabolic profiling along with 115 other clinical compounds with known modes of action. Allman et al. 24 measured changes in 113 116 metabolites after treatment with KAF156. These data did not show a clear metabolic 117 perturbation, in contrast to inhibitors of cytochrome bc1, dihydroorotate dehydrogenase, 118
PfATP4, or dihydrofolate reductase, many of which are also active in both blood and hepatic 119 stages. 120
Given the clinical potential of GNF179, determining its mechanism of action could reveal 121 important new druggable pathways, suggest synergistic drugs that could be used in combination 122 therapies, and provide clues on possible toxicity. Here we report on a series of experiments in P. 123 falciparum and S. cerevisiae to discern the mode of action of this important antimalarial 124 compound series. 125
RESULTS
126
Identifying potential targets of GNF179 using S. cerevisiae model system genetics. 127
For target identification, we first used in vitro evolution studies in the model system 128
Saccharomyces cerevisiae, a strategy that has been used to discover the target of cladosporin, a 129 tRNA synthetase inhibitor that acts against both P. falciparum and S. cerevisiae. IZPs are 130 moderately active against an attenuated strain of Saccharomyces that had been genetically 131 modified by replacing 16 ABC multi-drug transporter genes with modified Aequorea victoria 132 GFP (eGFP) and that has been dubbed the "Green Monster" 25 . Altogether 13 different, 133 independent IZP-resistant yeast lines were created by growing the cells for a minimum of 20 134 generations in the presence of increasing GNF179 concentrations until resistance was observed 135 (with a minimum 1.5x IC 50 increase for GNF179). Clonal lines were isolated from each resistant 136 culture and retested for sensitivity. The observed resistant strains exhibited 1.5 -3.1-fold 137 resistance relative to the drug-naïve Green Monster strain. 138
We sequenced drug-resistant genomes to an average 47.3x coverage and compared these 139 to the drug-sensitive parent (Table S1 ). Excluding mutations in repetitive elements, we detected 140 67 total variants including 49 missense, frameshift or nonsense variants, 2 synonymous variants, 141 2 inframe deletions and 14 intergenics (Table S2 ). The high proportion of coding to silent 142 mutations suggests that most changes have a beneficial effect. Multiple independent alleles were 143 found in six different genes arising in independent selections (sec66(2 variants), elo2(5), lcb4(3), 6 YMR102C(4), atg15(4) and sur2(3)), with the most resistant lines harboring multiple mutations 145 (e.g. GNF179-R19g2 with YMR102C, atg15 and sur2) although not generally in catalytic 146 domains (Figure 1a ). With ~5800 genes in the genome, the probability of finding more than one 147 allele by chance in the same gene after in vitro evolution is very low (p = 4.4 e -7) and highlights 148 the reproducibility of the selections. In addition, the set of 38 variants included singletons in the 149 closely related genes sur1, elo3, and atg22. This mutational pattern is specific to IZPs and has 150 not been observed for in vitro evolution with other antimalarial compounds whose targets have 151 been identified using the Green Monster system 26, 27 . 152
With the exception of YMR102C, whose function is not known, these genes are all 153 directly or indirectly associated with trafficking and processes in the ER (Figure 1b ). SEC66 154 encodes a non-essential subunit of the SEC63 complex that forms a channel competent for SRP-155 dependent and post-translational SRP-independent protein targeting and import into the ER. 156 SEC66 disruption is well known to slow the process of protein trafficking, such that trafficking 157 intermediates become evident by gel electrophoresis 28 . Similarly, ELO2 and ELO3, which 158 encode fatty acid elongases that contribute to sphingolipid biosynthesis in the ER, were 159 identified in a protein trafficking screen: Alleles in both ELO2 and ELO3, named VBM1 and 160 VBM2, 29 were identified as suppressors of a v-SNARE mutant in which yeast cells accumulate 161 post-Golgi secretory vesicles, and are defective in invertase secretion. 30 ATG15 and ATG22 play 162 a role in autophagy, which is induced in proteasome-independent ER expansion that results from 163 aggregates of misfolded proteins. SUR1 (the catalytic subunit of mannosylinositol 164 phosphorylceramide (MIPC) synthase that is required for biosynthesis of mature sphingolipids), 165 SUR2 (sphingosine hydroxylase involved in sphingolipid metabolism), and LCB4 (sphingoid 166 long-chain base kinase) are all part of the sphingolipid metabolism pathway, which is carried out 167 in the ER. Sphingolipids and long chain fatty acids play a role in regulating autophagy. The 168 identification of resistance-conferring genes whose products are localized to the ER or Golgi is 169 similar to observations in P. falciparum. 170
As these resistant strains often harbored multiple mutations, we used CRISPR-Cas9 171 based genome editing to introduce these mutations in a drug-naïve Green Monster genetic 172 background. For sec66 (M1I, IC 50 = 70.1 µM, S107*, IC 50 = 74.82 µM), elo2 (G183C IC 50 = 173 88.15 µM) and elo3 (Y307*, IC 50 = 76.56 µM) vs wild-type (WT) Green Monster IC 50 = 47.3 174 µM (Table 2) , the CRISPR-edited lines exhibited similar, 1.5 to 1.9-fold levels of resistance to 7 the drug-pressure derived lines, indicating that these three genes were responsible for the 176 resistance observed in those yeast strains. 177 Some of the mutations (e.g. elo2, sur2, atg15 and sec66) were early stop codons and 178 therefore resulted in truncated proteins. To provide a further layer of confirmation for the in vitro 179 resistance experiments, the homozygous deletion strains (which are not attenuated like the Green 180 Monster strain) 31,32 for sec66, sur2, atg15 and elo2 were tested against GNF179, revealing each 181 to be 1.3-2.1-fold more resistant to IZPs (IC 50 = 121 µM (WT) vs 188 µM (sec66Δ), 255 µM 182 (elo2Δ) and 217 µM (sur2Δ) respectively). We found that the homozygous deletion strain for 183 yer140w (which encodes the PfCARL homolog EMP65 33 ) showed low-level resistance to IZPs 184 (152 µM), and a homozygous deletion of sec72, another nonessential subunit of the complex for 185 importing proteins into the ER, also conveyed a similar level of resistance (177 µM) (Table 3) . 186
These data suggest that modifications to either the protein export complex or lipid synthesis 187 pathways or both can result in IZP resistance in yeast. Although the observed mutations may 188 help overcome GNF179 treatment, it seems unlikely that these genes encode targets. Many genes 189 are not essential and we observe stop codons. In addition, levels of resistance for isolated alleles 190 are mild. 191 pfcarl mutant lines show altered sphingolipid profiles. To explore sphingolipid synthesis as a 192 direct mechanism of action, we used a HPLC (high pressure liquid chromatography) linked to 193 triple quadrupole mass spectrometry (LC-MS/MS) to measure 19 classes of sphingolipids in P. 194 falciparum Dd2 parasites exposed to 5x IC 50 (30 nM) GNF179 for 4 hours. Of note, prior work 195 has demonstrated mammalian-like sphingolipid biosynthetic activities in Plasmodium parasites 34 . 196 Results with Dd2 WT parasites were compared to the pfcarl triple mutant (KAD452-R3; M81I, 197 L830V and S1076I). LC-MS/MS analysis of saponin-lysed parasite extracts identified 198 dihydroceramides (DH), ceramides (C), sphingosines (So), sphinganines (Sa) and 199 sphingomyelins (SM), with varying fatty acid chains and degree of saturation ( Figure 2 ). 200
Normalized lipidomic comparison of untreated wild-type and mutant parasites indicated 201 that the baseline sphingolipid concentration was notably lower in the pfcarl mutant. As an 202 example, C18:1 dihydroceramide was undetectable in mutant parasites. Likewise, ceramide 203 levels (Figure 2b) in untreated wild-type parasites were found to be consistently higher than in 204 the mutant, with statistical significance being observed in 3 out of the 6 identified species (C16, 205 C20, C24). Notably, sphingomyelins (SM C18, SM C18:1) were significantly lower compared to 206 Dd2. These consistent differences observed in the pfcarl mutant line are supportive of shared 207 mechanisms of resistance to GNF179 between Plasmodium and yeast. 208
Dihydroceramides (Figure 2a ) in drug-treated WT and pfcarl mutant parasites tended to 209 decrease and increase in concentration, respectively, compared to the untreated parasites. The 210 increase in pfcarl mutants upon GNF179 treatment was significant for the species C24 and 211 C24:1. Sphingosines and sphinganines (Figure 2c ) demonstrated consistent trends in the 212 sphingolipid profile in that a slight decrease was observed when wild-type parasites were treated 213 with drug. The mutant exhibited a slightly different profile in that when treated, the sphingolipids 214 So and Sa increased but So-1-P and Sa-1-P either remained the same or decreased slightly in 215 concentration. None of the trends observed, however, attained statistical significance. 216 Sphingomyelins ( Figure 2d ) showed no significant changes upon treatment of either WT or 217 mutant parasites. 218
Localization of GNF179 within the parasite. To gain further insight into the 219 compound's function we next examined subcellular localization using a fluorescently-conjugated 220 form of GNF179 in P. falciparum, as recently performed for primaquine 35 . We first generated 221 both NBD-or Coumarin-1-conjugated forms of GNF179 (Figure 3a ), leveraging an existing 222 reaction series 36 . These modified compounds retained activity against P. falciparum blood 223 stages, though the potency was noticeably reduced for the Coumarin-1 conjugated form of 224 GNF179 (19 nM for NBD and 1.2 µM Coumarin-1 vs 5 nM for non-modified GNF179). 225
However, the GNF179-resistant strain (KAD452-R3) was also resistant to the modified forms of 226 GNF179 (Figure 3b ), indicating a similar mechanism of action for the labeled and unlabeled 227 compounds. We first examined the localization of GNF179 in ring-stage parasites, as previous 228 reports indicated that GNF179 is most active against early blood stages 22 . GNF179 colocalized 229 with ER tracker Red, a live-cell dye that recognizes the ER 37 ( Figure 3c ). This, combined with 230 the S. cerevisiae data and the localization of the three previously identified resistance genes 231 (pfact, pfugt and pfcarl) to the ER/Golgi, suggest that IZPs affect a process within this 232 compartment. 233 GNF179 inhibits protein export in P. falciparum. To further explore the hypothesis 234 that GNF179 blocks the production or sorting of mature proteins, we next tested for synergy with 235 known protein-export inhibitors. Brefeldin A inhibits Sec7-type GTP-exchange factors (GEFs) 236 that catalyze the activation of a small GTPase called Arf1, responsible for ER to Golgi transport, 237 as well as Golgi to ER retrograde transport, through the inhibition of COPI coating of secretory 238 vesicles 38 , and is commonly used to inhibit protein secretion. We observed that treating parasites 239 with sublethal concentrations of brefeldin A (1µM) rendered parasites 5-fold more sensitive to 240 GNF179 (IC 50 of 0.6 nM, vs 3 nM without brefeldin A co-treatment) (Table 4) , while sensitivity 241 to the control drug artemisinin was unchanged. This suggests that parasites exposed to GNF179 242 are highly sensitive to alterations in protein export. 243
A similar effect was observed for golgicidin, another inhibitor of protein export that 244 works through inhibition of Golgi function 39 . Simultaneous treatment with 5 µM golgicidin (IC 50 245 11µM) also rendered parasites 2-3-fold more sensitive to GNF179 (Table 4 ). Importantly, this 246 effect was specific to GNF179, rather than merely a sign of generalized parasite growth 247 impairment, as artemisinin, atovaquone and chloroquine all showed no synergy with any of these 248 three compounds. This synergistic effect was exclusive to inhibitors of protein secretion from the 249 ER and Golgi, as simultaneous treatment with thapsigargin, which inhibits PfATP6 and causes 250 depletion of ER calcium levels leading to downstream inhibition of ER chaperones 40 , caused no 251 change in GNF179 potency. In addition, we tested for synergy between GNF179 and inhibitors 252 of the P. falciparum proteasome (Table 4) , to determine whether the identified increase in 253 ubiquitinated proteins was directly involved with the efficacy of GNF179 or rather was a 254 downstream consequence. We did not observe any synergy between GNF179 and carmaphycin 255 B, a natural product-derived proteasome inhibitor 27 . This is in contrast to artemisinin, which 256 increases the potency of carmaphycin B. This indicated to us that the increase in protein 257 ubiquitination was a secondary effect of GNF179 inhibiting protein trafficking, rather than a 258 direct cause. 259
To examine whether protein secretion was being blocked, we sequentially looked at 260 protein processing in P. falciparum. In free-living organisms, proteins are trafficked to 261 membranes or to the extracellular environment. In intracellular malaria parasites, however, 262 proteins can be further exported into the infected red blood cell (RBC) or hepatocyte via the 263 PTEX complex, a parasite-specific secretory complex located in the parasitophorous vacuole 264 membrane 41 . To examine these two processes, we used two different transiently-expressed 265 reporters. The first reporter (Figure 4a Based on where the export pathway is blocked three different potential protein products may be 274 observed, the full length fusion protein, the PEXEL-domain cleaved protein, and mature GFP. 275
As a control, we used WEHI-842, a peptide mimetic Plasmepsin V inhibitor (EC 50 = 400 nM) 42 . 276
Treatment with WEHI-842 showed a marked accumulation of the full-length, unprocessed 277 protein relative to the untreated control, as expected, given the role of Plasmepsin V in cleavage 278 of PEXEL signal sequences. Parasites treated with high doses of GNF179, on the other hand, 279 showed a marked decrease in levels of all forms of the secreted reporter construct, with little 280 evidence of cleavage ( Figure 4a ). In contrast, levels of HSP70 protein, which does not have a 281 signal sequence, were unchanged after treatment with GNF179 or WEHI-842. This finding 282 suggests that proteins trafficked through the ER, but not cytoplasmic proteins, are being 283 degraded or potentially not being synthesized due to exposure to GNF179. 284
The second reporter construct was a SERA5ss-GFP fusion, containing the signal peptide 285 of SERA5 (PF3D7_0207600) fused to GFP ( Figure 4b ). SERA5 is an exported serine protease 286 that plays a role in parasite egress from the infected RBC 43 . This fusion protein is co-287 translationally inserted to the ER and the signal peptide is removed by a signal peptidase, leading 288 to trafficking of the mature protein to the parasitophorous vacuole (PV) 43 . SERA5ss-GFP is 289 therefore used as a marker of protein secretion to the PV, versus the infected RBC. Without 290 treatment, we observed two protein products for this chimera using GFP antibodies. After 291 exposure to GNF179, the reporter showed a marked decrease in overall abundance relative to the 292 HSP70 control, as observed for PfEMP3 reporter above ( Figure 4b ). In addition to marked 293 overall reduced expression, we also observed an accumulation of the unprocessed reporter 294 protein, based on the overall ratio of the two products. Based on results with these two reporter 295 systems, we speculated that there was an impairment of protein secretion that occurs before 296 signal peptide cleavage, leading to degradation of the uncleaved products or potentially a block 297 in synthesis. Although this could be a result of reduced total protein synthesis, we observed 298 continued incorporation of 35 S methionine after treatment with GNF179, in contrast with 299 cycloheximide. Thus, if protein synthesis was inhibited, it was likely to only be for a subset of 300 proteins. To test whether the loss of reporter signal via western blot could be due enhanced 301 proteolysis through the ubiquitin system we compared the effects of MG132, a proteasome 302 inhibitor, on cleaved and uncleaved reporter levels both in the presence and absence of GNF179. 303
These data showed that proteasome inhibition, in contrast to GNF179 inhibition, did not affect 304 the levels or processing of either the PfEMP3 or the SERA5 reporter and that there was no 305 observed synergy with GNF179 ( Figure S1 ). Interestingly, increases in total ubiquitinated 306 proteins were observed after both MG132 and GNF179 treatment, although banding patterns 307 were somewhat different suggesting that different classes of proteins could be ubiquitinated after 308 treatment with the two compounds. 309
We also tested whether native parasite proteins that are normally exported to the 310 surrounding infected RBC would be retained within the parasite after exposure to GNF179. We 311 therefore examined the intracellular levels of three PEXEL-containing proteins: PTP2 312 (PF3D7_0731100), PIESP2 (PF3D7_0501200) and SERA5 (PF3D7_0207600). In all three 313 cases, after a short, 3-hour exposure with 10µM GNF179 (same conditions as above for the 314 reporters for both GNF179 and WEHI-842) ( Figure S2 ), we observed a modest accumulation of 315 all three proteins suggesting impairment of protein export from the parasite ( Figure S2 ). A 316 conditional knockdown of PfSEC62 using the glmS ribozyme system 44,45 showed that parasites 317 were 3-fold more sensitive to GNF179 (0.66 nM for 3D7 wildtype vs 0.24 nM for PfSEC62 kd) 318 ( Figure S3 ). 319
Finally, we validated the effect of GNF179 on parasite protein export in live parasites 320 through two parallel strategies, using brefeldin A (BFA) as a positive control: visualization of 321 export of fluorescent reporter proteins, and examination of functional phenotypes that would 322 result from inhibition of protein secretion. To begin, we constructed a parasite strain that bears a 323 fusion between the Knob-Associated Histidine Rich Protein and GFP 44 (Figure 5a ). The chimeric 324 gene, which bears the first 69 amino acids of KAHRP containing the signal peptide (SP) and 325 PEXEL motif (Px), was expressed from a pfcrt promoter and was integrated into the cg6 locus in 326 Dd2-attB parasites using the attP × attB integrase system 45 . In the absence of GNF179 the GFP 327 reporter was trafficked to the parasitophorous vacuole (PV) as well as to the RBC cytosol, as 328 shown by the GFP staining in the PV surrounding the parasite (Figure 5b ). In contrast, treatment 329 with brefeldin A resulted in accumulation of the GFP reporter in the parasite ER as evidenced 330 when co-staining with an anti-PDI antibody (cyan) or by using ER tracker red (Figure 5b and 331 Figure S4 ). The white dotted outlines indicate overlap of green and cyan labels. To better 332 understand in which subcellular compartment the export block occurred we co-stained with 333 antibodies to both the cis-Golgi resident protein, ERD2, 46 and to the ER (PDI)). In contrast to 334 BFA -treated parasites, images of parasites treated with 5x IC 50 GNF179 (25 nM) for 16 hours 335 showed colocalization of the GFP signal at times with both organelles (Figure 5c ), although we 336 found more colocalization with the ER than with the Golgi (area circles with white dotted lines). 337
Interestingly, staining of parasites with ER-tracker after GNF179 treatment showed an expansion 338 of ER tracker positive space relative to nuclear staining ( Figure S4 a-c). 3D volume 339 quantification of the ratio between DAPI-positive staining to ER-staining in live, GNF179-340 treated parasites showed a statistically-significant expansion of the ER ( Figure S4d ). 341
342
To functionally confirm a secretion defect, we next determined whether parasites treated 343 with GNF179 would be less sensitive to sorbitol treatment, which kills mature parasites and is 344 used to synchronize cultures as only ring-stage parasites survive. For sorbitol to kill later stage 345 parasites, the new permeability pathways (NPPs) must first be established in the RBC, which 346 requires the export of a network of transport proteins 49 ( Figure 5e ). Here, we observed that 4 347 hours of pretreatment with 25 nM GNF179 led to a loss of sensitivity to sorbitol, as seen via the 348 presence of a nearly asynchronous culture 24 hours post synchronization (Figure 5f ). This was in 349 contrast to parasites that were GNF179 resistant, resulting from mutations in either pfcarl 350 (KAD452-R3, Figure 5f ) or, to a lesser degree, pfact (Dd2-ACTStop, Figure 5f ). Those resistant 351 parasites showed less protection and more sorbitol lysis. As controls we observed a similar 352 phenotype with brefeldin A but not with chloroquine. The lack of sorbitol sensitivity in the 353 presence of GNF179 further highlights the impairment of ER-mediated protein trafficking due to 354 GNF179 exposure. 355
DISCUSSION
356
Once the parasite has successfully invaded the host cell, the parasite undergoes a rapid 357 induction of protein synthesis 50 . This includes the folding and sorting of hundreds of membrane 358 proteins and the secretion of hundreds of proteins into the host cell via the parasite ER and the 359 PTEX complex in the PVM, leading to a dramatic rearrangement of host cell processes, all 360 essential for parasite survival. Proteins needed for these essential processes may make effective 361 drug targets, as shown by the development of WEHI-842, an inhibitor of Plasmepsin V 51 . In 362 addition, KDU691 targets PI4K 52 , a protein involved in a variety of processes including vesicular 363 trafficking from the Golgi apparatus. While the trafficking of proteins into the infected RBC may 364 only occur during the asexual blood stage, general trafficking and protein modification is a 365 process that occurs, at least to some degree, at all stages of parasite development. Therefore, 366 proteins that play a role in protein processing or sorting pathways would be logical targets for the 367 type of multistage (hepatic, asexual blood and gametocyte stages) activity possessed by KAF156. 368
The ER serves as the initial entry into the protein trafficking and secretion pathways, as a 369 site for protein folding, and as the location of a significant portion of the post-translation 370 modification of parasite proteins. All of our available data suggest that KAF156 exerts its effect 371 in this organelle, including the localization of gene products that give resistance (in both S. 372 cerevisiae and P. falciparum) to KAF156/GNF179 as well as the localization of NBD and 373
Coumarin-labeled compounds. The ER is responsible for many functions, including lysine 374 acetylation, protein folding, glycosylation and sphingolipid biosynthesis ( Figure S5 ). After 375 proteins have been modified and folded, they are sorted to other compartments. While KAF156 376 may block the sorting of proteins to other compartment, our data seem more compatible with this 377 agent working at an earlier stage, protein-production stage, possibly during protein folding: 378
Western blot analysis shows a substantial reduction in the total amounts of secreted reporter 379 proteins relative to cytoplasmic proteins after GNF179 treatment, suggesting that the synthesis of 380 both membrane and PTEX-trafficked proteins may be disrupted. The reduction in protein levels 381 is in contrast to using the WEHI-842 inhibitor of the ER-based Plasmepsin V export protease, 382 where a shift from the processed to the unprocessed form of the protein is observed yet protein 383 reporter levels stay high. Levels of proteins that are not exported to the RBC but have a simple 384 signal sequence are also reduced ( Figure 4 ). 385
While a block in the synthesis of membrane proteins might be expected to result in an 386 unfolded protein response, and synergy with proteasome inhibitors such as carmaphycin B, there are different degradation pathways for cytoplasmic proteins versus proteins that are destined to 388 be secreted. Recent data reveal the existence of two pathways for dealing with protein aggregates 389 in the ER: ERAD(I) and ERAD(II) 53 . The second pathway depends on autophagy and lysosomal 390 trafficking for the disposal of large protein aggregates, and is observed in human cells when 391
Acetyl-CoA Transporter is disrupted 54 . It is likely that ERAD(II) is used when secreted reporters 392 (e.g. KAHRP69-GFP) are overexpressed, as we observed no great increase in ubiquitinated 393 proteins after GNF179 treatment except when a proteasome inhibitor (MG132) was used in 394 combination with GNF179 ( Figure S1 ). An expansion of the ER, similar to that observed after 395 GNF179 treatment in malaria parasites ( Figure S4 ), is observed when yeast cells are treated with 396 agents that induce the unfolded protein response. ER expansion induces autophagy as a 397 mechanism to deal with ER-stress and eliminate the blockage 55 . 398
Although GNF179 appears to work in the ER, the exact target of GNF179 is not known. 399
On the other hand, the cancer and antinfectives drug discovery communities have explored this 400 organelle and its processes for targets (reviewed in 56 ). The ER protein-folding factory examined 401 here also holds targets for antivirals as viruses need to be packaged within the ER 56 . In addition, 402 it has been established that the P. falciparum Signal Peptide Peptidase PfSPP1 is a drug-able 403 target and its inhibition results in parasite death across the lifecycle 57 . Conservation of critical 404 targets across species seems to be more the rule than the exception although selectivity of 405 inhibitors may be very different. 406
Although it is difficult to predict a target based on chemical structure, KAF156 has 407 structural features that suggest it may inhibit a kinase or other ATP or GTP binding proteins. 408
Many potential essential targets with ATP or GTP binding pockets are present ER-dependent 409 protein packaging pathway. Members of the Sec62 translocon complex could be possible targets. 410 However, Sec62 does not have an obvious catalytic site, a feature that is associated with many 411 targets, although it is possible that IZPs are allosteric inhibitors. Signal recognition particle 412 (SRP) is a protein complex critical for the translocation of proteins into the ER 58 . Within this 413 complex, both SRP54 and SRPα harbor GTPase domains, both of which would represent a prime 414 drug-able target. However, these data would not explain the increased ER volume that is 415 observed with GNF179-exposed parasites. Other candidates may include heatshock proteins 416 such as the GRP94-like protein endoplasmin (PF3D7_1222300). This essential protein has an 417 GRP94 homologs are not found in yeast and bacteria. However, GRP94 is somewhat 419 homologous to HSP82. In fact, in our yeast selections we detect a Ser to Ile substitution at 420 position 17 that lies in proximity to the ATP-binding pocket. However, the lack of a close 421 ortholog may explain the 10,000-fold difference in potency in the yeast model. In addition, 422 binding immunoglobulin protein (BiP), the Hsp70 homologue within the ER (PF3D7_0917900), 423
requires ATPase activity to perform the final step of protein translocation from the SEC61 424 translocon into the ER 60 and could also be a plausible target. Chemical targeting of BiP is 425 feasible. 61 The hypothesis that KAF156/GNF179 targets protein folding in the ER is supported 426 by the role of EMP65 as a guardian factor that protects newly synthesized, unfolded polypeptides 427 from degradation (See Figure S5 for model). If pfcarl-emp65 is mutated, more premature 428 degradation may occur in the presence of GNF179/KAF156, which may allow the cells to 429 tolerate 10X more GNF179. 430
Another potential class of proteins are Rab GTPases. Given the synergy we observed 431 between GNF179 and brefeldin A, GNF179 could inhibit COPI-mediated transport from the ER 432 to the Golgi, similar to the mechanism of action of brefeldin A 62 . Sar1, an essential gene 433 involved in the Sec23 complex, for example, is a small GTPase that functions as a target in a 434 yeast brefeldin suppressor screen 62 . The lysine transferase that adds acetyl groups to nascent 435 peptides, helping them fold and which relies on PfACT activity could be a target. 436
Protein glycosylation in the ER may could also be inhibited and may lead to unfolded 437 aggregates within the ER. Tunicamycin, a nucleoside analog, inhibits protein N-linked 438 glycosylation by preventing core oligosaccharide addition to nascent polypeptides by binding to 439 UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosamine phosphotransferase 440 (Alg7). Tunicamycin thereby also blocks protein folding and transit through the ER. The P. 441 falciparum version of Alg7, PF3D7_0321200, could theoretically be a target, although the 442 structure of KAF156 is not similar to tunicamycin. 443
It is although worthwhile noting that several additional compounds may work via similar 444 or related mechanisms. For example, mutations in pfcarl are acquired when parasites are treated 445 with sublethal concentrations of MMV007564 63 . In particular, if there is a pfcarl or pfact 446 resistance mechanism, it seems likely that protein folding or trafficking in the ER is targeted. 447
More work will be needed to determine whether MMV007564 has the same target as KAF156 or 448 if they are only in the same pathway. By comparison, there are a variety of different chemotypes 449 that inhibit mitochondrial function 64 , as well as different chemotypes that interact with the same 450 active site, however there still seem to be a limited number of high-value inhibitor binding sites 451 in this pathway, and they appear repeatedly. 452
An additional mechanism of action for IZPs could be inhibiting the process of ER 453 autophagy. The mammalian orthologue of Sec62, potentially a target of GNF179, is required for 454 the degradation of excess ER components in a process termed ER autophagy 65 . In vitro directed 455 evolution of S. cerevisiae using GNF179 identified mutations in the atg15 and atg22, genes that 456 play a role in ER-autophagy. In addition, GNF179 induced an expansion in ER size upon 457 treatment of P. falciparum. Collectively, these results suggest that IZPs affect ER homeostasis 458 and function by inhibiting proteins critical for ER-phagy. 459
Strategies for finding the target of KAF156 remain limited in the absence of genetic 460 methods, and few antimalarials have been matched with their target when genetic methods fail. 461
Affinity-based methods were used to match MMV030048 to PI4K with success 66 , although such 462 strategies required the use of a modified ligand. Cellular Thermal Shift Assays (CETSA) 463 methods that involve incubating total cellular extracts with an unmodified ligand and identifying 464 those proteins that resist heat denaturation in the presence of compound is a strategy that shows 465 promise 67 . Another potential option involves a genome-wide knockdown or knock-in libraries, 466
which have been used with success in trypanosomes and to find the target of cladosporin also 467 using the S. cerevisiae model 68 . A limitation of all of these genome-wide methods is that they 468 may produce hundreds of possible candidate molecules, and it can be challenging to sort through 469 them using the slow methods available in Plasmodium. While finding the exact target may 470 require some work, the studies here should allow prioritization of candidates that are identified in 471 genome-wide experiments. 472 
MATERIALS AND METHODS
Conjugation of Coumarin-1 and NBD with GNF179 526
GNF179 was conjugated with a coumarin-1 fluorophore as previously described 36 . 527
Briefly, Meldrum's acid was acylated with methyl 5-chloro-5-oxovalerate and subsequently 528 treated with methanol to provide coumarin β-keto ester. Next, the β-keto ester was first reacted 529 with resorcinol under acidic conditions and then hydrolyzed with lithium hydroxide to provide 4-530 rubber septum was charged with 7-dimethylaminocoumarin-4-acetic acid (4 mg, 0.016 mmol, 557 1.0 equiv.) and GNF179 (7 mg, 0.016 mmol, 1.0 equiv.) in dry DMF (0.2 mL). The solution was 558 cooled to 5 °C and solid EDC (4 mg, 0.023 mmol, 1.42 equiv.), HOBt (3 mg, 0.019 mmol, 1.2 559 equiv.) and neat DIEA (3 μL, 0.019 mmol, 1.2 equiv.) were added to the mixture. The solution as 560 stirred for 30 mins and the reaction was allowed to warm to ambient temperature and react for 18 561 hours. The reaction was then diluted with EtOAc (3 mL) and washed with water (1 mL). The 562 mixture was extracted with EtOAc (2 mL). The combined organic layers were dried over sodium 563 sulfate, filtered, and concentrated. The crude product was purified by silica column 564 chromatography, eluting with Hexanes: EtOAc (10: 90) affording the title compound (6 mg, 9.13 565 mmol, 63%) as yellow color solid. GNF179-NBD: To a stirred solution of GNF179 (6 mg, 0.014 mmol, 1.0 equiv.) and 4-chloro-7-581 nitrobenzofuran (3 mg, 0.014 mmol, 1.0 equiv.) in dry DMF (0.2 mL) was added neat DIEA (4 582 μL, 0.021 mmol, 1.5 equiv.). The solution was stirred for 16 hours at 23 °C. The reaction was 583 then diluted with EtOAc (2.5 mL) and water (1.2 mL) and the organic layer was collected. The 584 mixture was extracted with additional EtOAc (2 mL). The EtOAc layers were dried over sodium 585 sulfate, filtered, and concentrated. The crude product was purified by silica column 586 chromatography, eluting with Hexanes: EtOAc (40: 60) afforded the title compound (4 mg, 6.77 587 mmol, 52%) as light brown solid. 
Sphingolipid Quantitation 599
Parasites were grown in culture media containing both human serum (5%) and albumax 600 (0.25%) at 3% hematocrit. Asynchronous parasites (containing ~2/3 rd rings) were treated with 601 GNF179 for 4 hours at 5X wild type IC 50 (25nM). Parasitized cells were then washed with PBS 602 (+ drug for GNF179-treated samples). Samples were then lysed with 5 volumes of 0. Sphingolipids were normalized to protein and reported with respect to the mean ± SEM for n=3 628 independent experiments. Asterisks included in the tabulated data indicate statistical significance 629 at the 95% confidence interval determined using a two-tailed t-test (* p < 0.05, ** p < 0.01, *** 630 p < 0.001). n.d. denotes samples with insufficient data or lipid contents below the detection limit. 631
Immunoblotting to demonstrate Protein Trafficking Defects 632 P. falciparum parasites expressing PfEMP3-GFP or PfSERA5ss-GFP were generated as 633 previously described 41 ice. The saponin pellet was washed with 1x PBS, and then resuspended in 0.02% sodium 666 deoxycholate and supplemented with an equal volume of 16% trichloroacetic acid (TCA) to 667 make a final concentration of 8% TCA. The suspensions were then incubated for 20 minutes on 668 ice before vacuum filtration. To collect the radiolabeled, precipitated proteins, the samples were 669 dispensed onto 0.7µM glass fiber filter discs (Millipore, USA) that had been presoaked in 8% 670 TCA. The vacuum-filtered precipitates were then washed twice with 8% TCA and then, finally, 671 with 90% acetone. The filter discs were allowed to air-dry for at least two hours, transferred into 672 scintillation vials and resuspended in scintillation cocktail (Perkin Elmer, USA). 35 S counts were 673 obtained for 1 minute using a Beckman Coulter LS 6500 Multi-purpose Scintillation Counter. 674
Counts were normalized to data obtained from untreated parasites. 675
New Permeation Pathways Assessment of Sorbitol Synchronization Efficacy after GNF179 676
treatment 677
Parasites were cultured as above. Three parasite strains were used, wild-type Dd2, 678 KAD452-R3 and Dd2 ACT S242* (Dd2 act -PF3D7_1036800 -with S242* SNV 21 ). Each 679 parasite clone was split into 3 sets of matched cultures. Each set of matched cultures was either 680 treated for 4hr at 37°C with compound (50nM GNF179, 500nM Chloroquine or 5µM Brefeldin 681 A (Sigma Aldrich #B6542)) or an equal volume of DMSO. After drug treatment, cultures were 682 synchronized by treatment with 5% sorbitol (Sigma Aldrich # 240850) for 10min at 37°C, 683 washed once with media and returned to normal culture conditions. 24 hours after treatment, 684 cultures were assessed by thin blood smear and GIEMSA staining for parasite lifecycle stage. 685
The proportion of early ('ring') stage parasites to the total parasite proportion was recorded. 
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